Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare autoinflammatory and autoimmune diseases. The company markets ARCALYST (rilonacept) for recurrent pericarditis and deficiency of interleukin-1 receptor antagonist (DIRA), generating revenue from a niche orphan drug franchise with high pricing power. With 85.6% gross margins and accelerating revenue growth (56.6% YoY), Kiniksa is transitioning from development-stage losses to potential profitability as ARCALYST adoption scales.
Kiniksa generates revenue through direct sales of ARCALYST, an interleukin-1 alpha and beta blocker, to specialty pharmacies and hospitals treating ultra-rare patient populations. Pricing power is substantial given orphan drug status, limited competition in recurrent pericarditis (FDA approved 2021), and high unmet medical need. The company operates with a lean commercial infrastructure targeting ~200-300 prescribing cardiologists and rheumatologists, enabling high gross margins. Revenue scales as awareness builds among specialists and as real-world evidence supports broader adoption beyond initial launch cohorts.
ARCALYST quarterly prescription volume trends and net revenue per patient (key indicator of market penetration in recurrent pericarditis)
Clinical trial readouts for mavrilimumab in giant cell arteritis (Phase 3 data expected, could expand addressable market significantly)
Regulatory milestones including potential label expansions for ARCALYST in additional IL-1 mediated conditions
Quarterly operating expense trends and path to sustained profitability (currently near breakeven)
Competitive developments in autoinflammatory disease space, particularly from Novartis (Ilaris) and Regeneron
Regulatory risk from potential pricing reforms targeting orphan drugs, including IRA provisions that could impact future pricing flexibility for rare disease therapies after exclusivity periods
Clinical development risk for mavrilimumab pipeline - failure in Phase 3 giant cell arteritis trials would eliminate near-term growth catalyst and limit addressable market to current ARCALYST indications
Reimbursement pressure as payers scrutinize high-cost rare disease therapies, potentially requiring more extensive real-world evidence for coverage decisions
Direct competition from Novartis' Ilaris (canakinumab) in IL-1 mediated diseases, which has broader label and established market presence in autoinflammatory conditions
Potential entry of biosimilars or next-generation IL-1 inhibitors with improved dosing convenience or safety profiles
Competition for prescriber mindshare in crowded rare disease landscape, requiring sustained commercial investment to maintain awareness
Cash burn risk if operating losses persist beyond current runway - though near-breakeven status and strong current ratio mitigate near-term concerns
Dilution risk from future equity raises to fund pipeline development or commercial expansion, particularly if stock price declines from current elevated valuation levels
low - Rare disease treatments for life-threatening conditions like recurrent pericarditis are medically necessary and largely insulated from economic cycles. Patient demand is driven by disease incidence rather than discretionary spending. However, hospital budgets and specialty pharmacy reimbursement can face pressure during severe recessions, potentially delaying treatment initiation.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress valuation multiples for unprofitable biotech stocks, particularly impacting the 70.1x EV/EBITDA multiple; (2) increased financing costs for future capital raises, though current 3.85x current ratio and minimal debt (0.02 D/E) provide substantial cushion. Lower rates would support multiple expansion for growth-stage biopharma.
Minimal direct credit exposure. Revenue is primarily from specialty pharmacies and hospital systems with strong credit profiles. Payer mix includes commercial insurance and Medicare, both stable payment sources. The company's strong balance sheet (3.85 current ratio, negligible debt) eliminates refinancing risk.
growth - The 132.1% one-year return and 56.6% revenue growth attract momentum and growth investors focused on commercial-stage biotech with near-term profitability inflection. The elevated 5.6x P/S and 70.1x EV/EBITDA multiples reflect growth expectations rather than current earnings. Institutional investors focused on rare disease specialists with de-risked commercial assets and pipeline optionality are core holders.
high - Biotech stocks with single-product revenue concentration and binary clinical catalysts exhibit elevated volatility. The stock's 132% one-year gain demonstrates momentum characteristics. Small/mid-cap biotech beta typically ranges 1.3-1.8x, with event-driven spikes around clinical data releases and regulatory decisions. Limited analyst coverage and $3.3B market cap contribute to price sensitivity.
